ProfileGDS5678 / 1422652_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 11% 11% 11% 10% 11% 17% 12% 12% 11% 10% 11% 11% 11% 11% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.2867911
GSM967853U87-EV human glioblastoma xenograft - Control 22.2705111
GSM967854U87-EV human glioblastoma xenograft - Control 32.2711311
GSM967855U87-EV human glioblastoma xenograft - Control 42.20710
GSM967856U87-EV human glioblastoma xenograft - Control 52.2276911
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4711417
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.3202912
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.2705212
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.2472911
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.2478110
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.2547211
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.2516411
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.2630511
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.2636411